Prognostic Factors Of Erdheim–Chester Disease: A Nationwide Survey In Japan
EHA Library. Toya T. Nov 1, 2018; 234398 Topic: 5E Genetics and molecular biology
Takashi Toya
Takashi Toya
Journal Abstract

Co-Authors: Mizuki Ogura, Kazuhiro Toyama, Akihide Yoshimi, Aya Shinozaki-Ushiku, Akira Honda, Kenjiro Honda, Noriko Hosoya, Yukako Murakami, Hiroyuki Kawashima, Yasuhito Nannya, Shunya Arai, Fumihiko Nakamura, Yusuke Shinoda, Masaomi Nangaku, Kiyoshi Miyagawa, Masashi Fukayama, Akiko Moriya-Saito, Ichiro Katayama, Takashi Ogura, Mineo Kurokawa

Abstract: Erdheim–Chester disease is a rare histiocytosis with insufficient clinical data. To clarify the clinical features and prognostic factors of Erdheim–Chester disease, we conducted a nationwide survey to collect the detailed data of 44 patients with Erdheim–Chester disease in Japan. The median age of onset of the participants was 51 (range: 23–76) years, and the median number of involved organs per patient was 4 (range: 1–11). The existence of central nervous system disease was correlated with older age (P=0.033), the presence of cardiovascular lesions (P=0.015), and an increased number of involved organs (P=0.0042). The median survival from the onset was 10.4 years, and >3.0 mg/dL C-reactive protein level at onset was associated with worse outcome (median survival, 14.6 vs. 7.4 years; P=0.0016). In a multivariate analysis, age >60 years (hazard ratio, 25.9; 95% confidence interval, 2.82–237; P=0.0040) and the presence of digestive organ involvement (hazard ratio, 4.74; 95% confidence interval, 1.05–21.4; P=0.043) were correlated with worse survival. Fourteen patients had available histological samples of Erdheim– Chester disease lesions. BRAFV600E mutation was detected in 11 patients (78%) by Sanger sequencing. A correlation between BRAF mutation status and clinical factors was not observed. Our study revealed that age and digestive organ involvement influence the outcome of Erdheim–Chester disease patients, and an inflammatory marker, such as C-reactive protein, might reflect the activity of this inflammatory myeloid neoplasm.

Article Number: 1815

Doi: 10.3324/haematol.2018.190728

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies